By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile



1 North Waukegan Road

North Chicago  Illinois  60064  U.S.A.
Phone: 1-800-255-5162 Fax: n/a


AbbVie (NYSE:ABBV) is a global, research-based biopharmaceutical company. AbbVie’s mission is to apply the expertise, dedication, and creativity of its people to develop and market advanced therapies that address some of the world's most complex and serious diseases. AbbVie employs more than 28,000 people worldwide and markets medicines in more than 170 countries.

Oncology is a key therapeutic area for AbbVie, with a portfolio consisting of three marketed products — Imbruvica®, Venclexta™, and Empliciti™ — and a pipeline containing multiple promising new molecules that are being studied in nearly 200 clinical trials in 19 different types of cancer.

AbbVie is expanding its oncology hub on the West Coast, with three sites in the San Francisco Bay Area (Redwood City, South San Francisco, and Sunnyvale) focused on the discovery and development of novel oncology therapies. More than 1,000 AbbVie scientists, clinicians, and product developers with strong entrepreneurial roots work across these three sites. They combine their expertise in immuno-oncology, stem cells, and cell-signaling with their knowledge of bispecific antibodies, antibody-drug conjugates (ADCs), and covalent-inhibitor technologies to discover and develop novel cancer treatments.




CEO: Richard A. Gonzalez

CFO: William J. Chase


Please click here for Abbvie job opportunities.


Please click here for clinical trial information..


Key Statistics

Ownership: Public

Web Site: AbbVie
Symbol: ABBV

Company News
AbbVie (ABBV) Declares Quarterly Dividend 2/20/2017 6:45:13 AM
AbbVie (ABBV) Announces $5 Billion Increase To Stock Repurchase Program 2/17/2017 7:22:11 AM
A Look at Whether AbbVie (ABBV) Could Eventually Face the Same Issues as Gilead (GILD) 2/17/2017 6:36:22 AM
AbbVie (ABBV) Reports Full-Year and Fourth-Quarter 2016 Financial Results 1/27/2017 12:17:23 PM
AbbVie (ABBV) Release: Pharma Initiates Phase 2 Clinical Trial Programs For ABBV-8E12, An Investigational Anti-Tau Antibody, In Early Alzheimer's Disease And Progressive Supranuclear Palsy 1/25/2017 8:23:26 AM
Enanta Pharmaceuticals, Inc. Release: Pharma Announces EMA Grants Accelerated Assessment, Validates Marketing Authorization Application For AbbVie (ABBV)’s Investigational HCV Regimen Of Glecaprevir/Pibrentasvir (G/P) For The Treatment Of All Major Genotypes (GT1-6) Of Chronic Hepatitis C 1/24/2017 8:19:29 AM
AbbVie (ABBV) Release: EMA Grants Accelerated Assessment, Validates Marketing Authorization Application For Pharma's Investigational Regimen Of Glecaprevir/Pibrentasvir (G/P) For The Treatment Of Chronic Hepatitis C In All Major Genotypes (GT1-6) 1/24/2017 7:17:57 AM
Earnings Preview: Here's a Look at What to Expect From 7 Biopharmas 1/23/2017 6:22:30 AM
AbbVie (ABBV) Release: U.S. FDA Approves Imbruvica (Ibrutinib) As First Treatment Specifically Indicated For Relapsed/Refractory Marginal Zone Lymphoma (Mzl) - A Rare Type Of Non-Hodgkin's Lymphoma 1/19/2017 7:23:07 AM
Zebra Biologics To Collaborate With AbbVie (ABBV) To Discover New Antibody Therapeutics 1/9/2017 10:54:31 AM